Trade Names:Midamor- Tablets 5 mgApo-Amiloride (Canada)
Interferes with sodium reabsorption at distal tubule, resulting in increased excretion of water and sodium and decreased excretion of potassium.
15% to 25% is absorbed; t max is 3 to 4 h.
About 23% is protein bound.
T 1/2 is 6 to 9 h. About 50% is excreted unchanged in the urine; about 40% in the feces.
Within 2 h.
6 to 10 h.
Treatment of CHF or hypertension (in combination with thiazide or loop diuretics) and diuretic-induced hypokalemia.
Reduction of lithium-induced polyuria; slowed reduction of pulmonary function in patients with cystic fibrosis (aerosol form).
Serum potassium more than 5.5 mEq/L; potassium supplementation; impaired renal function: spironolactone or triamterene therapy.
PO 5 to 10 mg/day.Lithium-Induced Polyuria
PO 10 to 20 mg/day.Cystic Fibrosis
Dissolve in 0.3% saline and deliver by nebulizer.
Store in tightly closed container in cool location.
May result in severely elevated serum potassium levels.Potassium preparations
May severely increase serum potassium levels, possibly resulting in cardiac arrhythmias or cardiac arrest. Do not administer to patients taking potassium preparations.
None well documented.
Angina pectoris; orthostatic hypotension; arrhythmia.
Headache; dizziness; encephalopathy; paresthesia; tremors; vertigo; nervousness; mental confusion; insomnia; decreased libido; depression.
Skin rash; itching; pruritus.
Visual disturbances; tinnitus; nasal congestion.
Nausea; anorexia; diarrhea; vomiting; abdominal pain; gas pain; appetite changes; constipation; GI bleeding; abdominal fullness; thirst; dry mouth; heartburn; flatulence.
Impotence; polyuria; dysuria; urinary frequency.
Aplastic anemia; neutropenia.
Increased serum potassium levels.
Musculoskeletal (eg, weakness; fatigue; muscle cramps; joint/back/chest pain; neck or shoulder ache).
Monitor for signs of hyperkalemia (eg, fatigue, muscle weakness, cardiac irregularities).
Category B .
Safety and efficacy not established.
Use cautiously in patients with this condition.
With severe liver disease, hepatic encephalopathy (eg, tremors, confusion, coma, jaundice) may occur.
Hyperkalemia may occur.
If ECG changes occur (eg, peaked T waves, abnormal S or P waves), withhold dose and notify health care provider.
Hyperkalemia, hyponatremia, hypochloremia, and increases in BUN may occur.
If sudden elevation in serum potassium level (more than 5.5 mEq/L) occurs, withhold dose and notify health care provider.
Copyright © 2009 Wolters Kluwer Health.